Establish a strategic partnership with Eli Lilly to jointly develop glucokinase activator (GKA) ly2608204

Yabao Pharmaceutical (Shanghai Securities: 600351) announced in June 2014 that it had established a strategic partnership with Eli Lilly to jointly develop the glucokinase activator (GKA) ly2608204 in the industry. The project has completed phase I clinical in the United States and has rich preclinical development data.
Diabetes is a disease that is not satisfied in China and around the world. Unlike other diabetes drugs, glucokinase activator has two potential potent effects: promoting insulin secretion and reducing glucose production in the liver. Therefore, glucokinase activators have potential hyperglycemic inhibitory effects even in patient populations where other oral drugs are relatively ineffective.
According to the terms of the agreement, Yabao pharmaceutical will get the right to develop and sell in China, and Lilly reserves the right to all other markets. The two sides will cooperate to jointly determine the strategic development plan of China, Yabao will be responsible for the implementation and investment projects, and Lilly reserves the right to purchase in China in the future. The financial terms were not disclosed.
"Lilly's GKA is an optimized molecule, probably in that category. The company is pleased to work together with the global Lilly company in the field of diabetes." Dr. Wang Peng, vice president and Research Institute of the Asia Pacific Company, said that the cooperation with Eli Lilly fully demonstrated the growing determination of the company in the field of medicine cooperation. Yabao will take advantage of its strong clinical and regulatory advantages to bring new drugs to Chinese patients suffering from diseases. "
About Yabao pharmaceutical
Yabao Pharmaceutical (Shanghai Securities 600351) is a Chinese pharmaceutical enterprise with perfect drug development, production and commercialization capacity in China. Recently, Yabao has adjusted its strategic development direction, aiming at the field of innovative drugs in addition to its mature cause in the field of modern Chinese traditional medicine and chemical generic drugs. Yabao has strong clinical and regulatory capabilities. The production of preparations and APIs meets the requirements of drug production quality management practices (CGMP) and has passed the inspection of FDA and EU drug regulatory authorities respectively.

Next:Authorized cooperation was reached with Lawson Health Institute to develop and sell annexin A5 for the treatment of sepsis